The Importance Of Strain Selection In Cannabis For Depression
Published on: March 25, 2025
the importance of strain selection in cannabis for depression featured image
Article author photo

Chutimon Dolwasin

Article reviewer photo

Malavika Jalaja Prasad

MSc Nanomedicine, Swansea University

Introduction

Overview of cannabis use for depression

Increasing interest in cannabis as an alternative treatment for depression

Depression is a significant mental health condition, with 1 in 4 individuals experiencing at least one depressive episode during their life. While antidepressant medications are used to manage depression, their effectiveness and side effects are variable, leading to the exploration of alternative treatments. Research has shown that cannabinoids may help alleviate depression symptoms, as demonstrated in preclinical studies. This has increased interest in medicinal cannabis as a potential option for managing depression.1 

Importance of choosing the right strain for therapeutic benefits

Choosing the appropriate strain is important for maximising its therapeutic effects. Each strain contains various amounts of cannabinoids, such as tetrahydrocannabinol (THC), cannabidiol (CBD), or terpenes, which provide different effects. Some strains can be used to manage depression, but some strains may give unwanted side effects. Therefore, selecting the right strain can promote an effective and safe profile and minimise risks.

Role of cannabinoids and terpenes in depression

Key compounds in cannabis are THC, CBD, and terpenes. CBD is a substance naturally found in Cannabis sativa or hemp, which is non-psychoactive. Unlike tetrahydrocannabinol (THC), one of the cannabinoids can be addictive.2

Understanding Cannabis Strains

Indica, Sativa, and hybrid strains

There are two main types of medical cannabis strains: Indica and Sativa. These two strains can also combine and result in hybrid strains. The distinct properties in each are designed to have targeted effects on certain health conditions.3 

Cannabis sativa can provide a mood-boosting or anxiolytic effect, helping people feel more energised or alert because this strain contains higher doses of THC rather than CBD coupled with terpenes that give a stimulating effect. However, THC can lead to addiction.3

Indica strains are often associated with relaxing effects, reducing pain, increasing appetite, and helping sleep. Moreover, they contain higher levels of CBD and terpenes, which also provide relaxation.3

Cannabinoid profiles

THC-dominant strains for mood elevation

Cannabinoids can show dose-dependent and biphasic effects on cannabinoid receptors in animal models. THC can bind CB1 receptors and alleviate depressive symptoms.4 Low doses of THC show anxiolytic effects, but high doses of THC can promote anxious impacts.5

CBD-dominant strains for relaxation and anxiety relief

Cannabidiol is a non-psychotomimetic component that has various promising beneficial effects. CBD is related to depression mechanisms such as increasing a significant hormone, promoting connections between neurones, and increasing the production of neurones.6 These lead to abilities to cope with psychotic, anxiety, and withdrawal symptoms.6

Role of terpenes

Terpenes like limonene, linalool, and myrcene in mood regulation  

Terpenes such as limonene, linalool, and myrcene contribute to mood regulation through their distinct properties. Limonene, found in citrus and lemon, has been associated with anxiolytic effects in animal experiments and improved mood due to modulated serotonin receptors and increased serotonin levels. Linalool, found in lavender, has calming effects and sedation. It interacts with the GABA system in the brain (a key system that helps reduce nervous activity), leading to sedative, anxiolytic, and anticonvulsant effects (helps prevent seizures). Myrcene, present in hops, is recognised for its sedative properties and aid in relaxation and sleep, making it beneficial for managing stress-related conditions.7 

Synergistic Effects of Terpenes and Cannabinoids (Entourage effect)

The entourage effect refers to the enhanced therapeutic effects produced when terpenes and cannabinoids such as THC and CBD work synergistically. Terpenes, such as limonene and linalool, interact with cannabinoids by influencing their absorption, binding to receptors, and overall efficacy. For example, limonene may enhance the mood-lifting properties of THC, while linalool’s calming effects can counterbalance the psychoactivity of THC. This synergy allows for tailored effects, improving the treatment of mood disorders like anxiety and depression.8

Factors Influencing Strain Selection for Depression

Severity and type of depression

Chronic vs. situational depression

Chronic depression often requires long-term management strategies, which may include cannabis strains with consistent cannabinoid profiles, such as balanced THC-CBD strains. In contrast, situational depression might benefit from strains with uplifting terpenes like limonene for short-term relief.

Co-occurring conditions (e.g., anxiety, insomnia)

Cannabis strain selection may also depend on accompanying symptoms. For anxiety, CBD-dominant strains are often preferred due to their calming effects, while strains with myrcene can help individuals experiencing insomnia by promoting sleep.

Individual response to cannabis

Genetic factors and endocannabinoid system variability

Variations in genes that affect the endocannabinoid system, such as those coding for CB1 and CB2 receptors, can influence how individuals respond to cannabis. These genetic differences may impact how cannabinoids such as THC and CBD interact with the brain and regulate mood. For example, one gene will demonstrate an effective response to the treatment rather than people with another gene related to a poorer response. This explains why some people experience more significant therapeutic benefits or side effects than others, making personalised approaches to cannabis use important. However, there is limited evidence to rule out the reality of genetic factors affecting the endocannabinoid system.9

Tolerance and past cannabis use

Regular cannabis use over time can lead to the body becoming less sensitive to its effects, a condition known as tolerance.  It may decrease the activity of CB1 receptors, requiring higher doses to achieve the same effects. On the other hand, individuals new to cannabis often require lower doses, as their bodies are more responsive to its effects. Adjusting cannabis use based on prior exposure is critical to avoid negative experiences and maximise benefits.9

Method of consumption

Smoking, vaping, edibles, and tinctures

Cannabis can be used through various routes, such as smoking, eating, or vaporising. In each route of administration, there are also different modes of use. For example, smoking cannabis can be done via joint, blunt, bong, pipe, or water pipe.10

Differences in onset time and duration of effects

The different routes of cannabis consumption can affect the onset time, duration of the effects, and unwanted side effects. To illustrate, smoking can deliver THC to the brain more rapidly than the oral route, and this can lead to high levels of undesirable side effects and abuse. In addition, different modes of cannabis use may also be relevant to provide the differences in drug effects and outcomes. For example, smoking blunts can result in higher intoxication and withdrawal than other modes.10

Benefits of Strain Selection for Depression

Targeted symptom relief

Easing symptoms like low mood, fatigue, and insomnia

Specific cannabis strains can help manage core symptoms of depression. For instance, strains with uplifting terpenes like limonene or moderate THC levels may improve mood and energy, while strains high in CBD or myrcene can promote relaxation and alleviate insomnia.7

Minimising side effects like anxiety or lethargy

Choosing the right strain helps avoid negative effects such as increased anxiety from high-THC strains or lethargy from heavy Indica-dominant strains. Balanced strains with equal THC and CBD levels provide moderate effects and reduce the likelihood of adverse reactions.11

Improved quality of life

Enhancing productivity and emotional well-being

Appropriate strain selection tailored to an individual’s needs can improve daily functioning by addressing fatigue or emotional instability, which are common in depression. This can lead to increased productivity and better engagement in personal and professional life.12

Supporting mental health alongside conventional treatments

When used with traditional therapies such as antidepressants or psychotherapy, cannabis can complement these approaches by targeting specific symptoms like insomnia or anxiety that medications may not fully address.13

Risks and Challenges

Potential for adverse effects

Overuse of THC leads to increased anxiety or paranoia

Excessive use of THC-dominant strains may overstimulate the brain’s CB1 receptors, causing heightened anxiety or paranoia in sensitive individuals.14

Risks of dependency with improper use

Frequent or high-dose cannabis use, particularly with THC-rich strains, may lead to dependency over time, especially in those without structured usage plans.15

Lack of Standardisation

Variability in strain composition across providers

The chemical makeup of cannabis strains can differ widely among suppliers, which can lead to inconsistent results for users seeking therapeutic benefits.16

Limited research on cannabis strains and depression

While cannabis is widely used for mood disorders, there is a lack of robust clinical trials to identify the most effective strains for depression.7

Legal and Accessibility Issues

Even in regions with legalised cannabis, access to medical-grade products may be limited due to high costs or restricted availability, creating challenges for consistent use.14

Summary

Cannabis is a potential treatment for depression, emphasising the importance of choosing the right strain to enhance therapeutic benefits while reducing risks. It explains how cannabinoids like THC and CBD, along with terpenes such as limonene, linalool, and myrcene, play a role in mood regulation and symptom relief. The article outlines how strain types (Indica, Sativa, hybrids) impact symptoms like low mood, fatigue, and insomnia, with recommendations tailored to individual needs.

Key factors in strain selection include depression severity, individual genetics, tolerance levels, and consumption methods. While appropriate strain use can improve quality of life and complement traditional treatments, challenges such as potential side effects, inconsistent strain composition, limited research, and legal restrictions persist. The document calls for more research and personalised approaches to optimise cannabis use for depression management, ensuring safe and effective treatment options.

References

  1. Mangoo S, Erridge S, Holvey C, Coomber R, Barros DAR, Bhoskar U, et al. Assessment of clinical outcomes of medicinal cannabis therapy for depression: analysis from the UK Medical Cannabis Registry. Expert Rev Neurother. 2022;22(11–12):995–1008. Available from: https://pubmed.ncbi.nlm.nih.gov/36573268/
  2. Oberbarnscheidt T, Miller NS. The impact of cannabidiol on psychiatric and medical conditions. J Clin Med Res [Internet]. 2020 Jul [cited 2024 Dec 4];12(7):393–403. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331870/ .
  3. mamedicawebclinic. Mamedica. 2023 [cited 2024 Dec 4]. Indica vs. Sativa: the great debate. Available from: https://mamedica.co.uk/indica-vs-sativa-the-great-debate/ .
  4. Stoner SA. Effects of Marijuana on Mental Health: Depression. Alcohol & Drug Abuse Institute [Internet]. 2017 Jun; Available from: https://adai.uw.edu/pubs/pdf/2017mjdepression.pdf 
  5. Grunberg VA, Cordova KA, Bidwell LC, Ito TA. Can marijuana make it better? Prospective effects of marijuana and temperament on risk for anxiety and depression. Psychol Addict Behav [Internet]. 2015 Sep [cited 2024 Dec 4];29(3):590–602. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588070/
  6. Silote GP, Sartim A, Sales A, Eskelund A, Guimarães FS, Wegener G, et al. Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms. Journal of Chemical Neuroanatomy [Internet]. 2019 Jul 1 [cited 2024 Dec 4];98:104–16. Available from: https://www.sciencedirect.com/science/article/pii/S0891061818302114 
  7. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011 Aug;163(7):1344–64. Available from: https://pubmed.ncbi.nlm.nih.gov/21749363/
  8. Ferber SG, Namdar D, Hen-Shoval D, Eger G, Koltai H, Shoval G, et al. The “entourage effect”: terpenes coupled with cannabinoids for the treatment of mood disorders and anxiety disorders. Curr Neuropharmacol [Internet]. 2020 Feb [cited 2024 Dec 4];18(2):87–96. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324885/
  9. Lester KJ, Coleman JRI, Roberts S, Keers R, Breen G, Bögels S, et al. Genetic variation in the endocannabinoid system and response to Cognitive Behavior Therapy for child anxiety disorders. Am J Med Genet B Neuropsychiatr Genet [Internet]. 2017 Mar [cited 2024 Dec 4];174(2):144–55. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324578/
  10. Streck JM, Hughes JR, Klemperer EM, Howard AB, Budney AJ. Modes of cannabis use: a secondary analysis of an intensive longitudinal natural history study. Addict Behav [Internet]. 2019 Nov [cited 2024 Dec 4];98:106033. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708744/
  11. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015 Oct;12(4):825–36. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4604171/
  12. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001 Feb;178:101–6. Available from: https://pubmed.ncbi.nlm.nih.gov/11157422/
  13. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327–60. Available from: https://pubmed.ncbi.nlm.nih.gov/12648025/
  14. Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21–47. Available from: https://pubmed.ncbi.nlm.nih.gov/22804774/
  15. Bonomo Y. Cannabis use and dependence: public health and public policy, young people and substance abuse. BMJ [Internet]. 2005 Jan 1 [cited 2024 Dec 4];330(7481):49. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC539863/
  16. McPartland JM, Russo EB. Cannabis and cannabis extracts: greater than the sum of their parts? Journal of Cannabis Therapeutics [Internet]. 2001 Jun [cited 2024 Dec 4];1(3–4):103–32. Available from: http://www.tandfonline.com/doi/abs/10.1300/J175v01n03_08
Share

Chutimon Dolwasin

arrow-right